免疫检查点抑制剂在晚期非小细胞肺癌中的应用显著提高了患者的生存获益,但是现在临床上没有明确对于免疫治疗疗效预测的标记物,常见的PDL1、CTLA-4只能通过组织活检获得,如果能证明外周血相关指标对于疗效的预测,会更简便或者与组织学...免疫检查点抑制剂在晚期非小细胞肺癌中的应用显著提高了患者的生存获益,但是现在临床上没有明确对于免疫治疗疗效预测的标记物,常见的PDL1、CTLA-4只能通过组织活检获得,如果能证明外周血相关指标对于疗效的预测,会更简便或者与组织学综合考量后预测价值更高。本文将从血清标记物对免疫检查点抑制剂治疗晚期非小细胞肺癌预后基线及动态监测的相关研究进展进行综述。The application of immune checkpoint inhibitors in advanced non-small cell lung cancer has significantly improved the survival benefits of patients. However, there are no clear markers for predicting the efficacy of immunotherapy in clinical practice, and common PDL1 and CTA4 can only be obtained through tissue biopsy. If the prediction of efficacy of peripheral blood related indicators can be proved, the clinical curative effect can be more easily and dynamically predicted, or the predictive value of peripheral blood indicators combined with histology may be higher. This article reviews the progress of serum markers in baseline and dynamic monitoring of the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.展开更多
文摘免疫检查点抑制剂在晚期非小细胞肺癌中的应用显著提高了患者的生存获益,但是现在临床上没有明确对于免疫治疗疗效预测的标记物,常见的PDL1、CTLA-4只能通过组织活检获得,如果能证明外周血相关指标对于疗效的预测,会更简便或者与组织学综合考量后预测价值更高。本文将从血清标记物对免疫检查点抑制剂治疗晚期非小细胞肺癌预后基线及动态监测的相关研究进展进行综述。The application of immune checkpoint inhibitors in advanced non-small cell lung cancer has significantly improved the survival benefits of patients. However, there are no clear markers for predicting the efficacy of immunotherapy in clinical practice, and common PDL1 and CTA4 can only be obtained through tissue biopsy. If the prediction of efficacy of peripheral blood related indicators can be proved, the clinical curative effect can be more easily and dynamically predicted, or the predictive value of peripheral blood indicators combined with histology may be higher. This article reviews the progress of serum markers in baseline and dynamic monitoring of the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
